Association of Corticosteroids With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab

Félix Lefort; Cécile Dalban; Marine Gross-Goupil; Brigitte Laguerre; Sylvie Chabaud; Bernard Escudier; Laurence Albiges

doi:10.1001/jamaoncol.2023.2296

Association of Corticosteroids With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab

JAMA Oncol. 2023 Sep 1;9(9):1295-1298. doi: 10.1001/jamaoncol.2023.2296.

Authors

Félix Lefort¹, Cécile Dalban², Marine Gross-Goupil¹, Brigitte Laguerre³, Sylvie Chabaud², Bernard Escudier⁴, Laurence Albiges⁴

Affiliations

¹ Medical Oncology, CHU Bordeaux-Hopital St André, Bordeaux, France.
² Clinical Research, Centre Léon Bérard, Lyon, France.
³ Medical Oncology, Centre Eugene Marquis, Rennes, France.
⁴ Medical Oncology, Gustave Roussy-Cancer Campus, Villejuif, France.

PMID: 37440214
PMCID: PMC10346501 (available on 2024-07-13)
DOI: 10.1001/jamaoncol.2023.2296

No abstract available

Plain language summary

This nonrandomized controlled trial ancillary study evaluates the survival outcomes associated with corticosteroid use during nivolumab treatment for patients with metastatic renal cell carcinoma.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Antineoplastic Agents, Immunological* / adverse effects
Carcinoma, Renal Cell* / pathology
Humans
Kidney Neoplasms* / pathology
Nivolumab / therapeutic use
Retrospective Studies

Substances

Nivolumab
Antineoplastic Agents, Immunological
Adrenal Cortex Hormones